Floatz logo

Docetaxel

Stage III Urethral Cancer AJCC v8

Jonsson Comprehensive Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Stage III Urethral Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Vinflunine
Dr Anders Ullén
Phase 2BB
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Jonsson Comprehensive Cancer Center
Phase 1/2B
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Pembrolizumab
Emory University
Phase 2B

View all 30 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →